Treating chronic wounds is an expensive and time-consuming process. As the current protocol for wound management typically involves the use of different ointments and liquid solutions, specialized bandages, topical skin substitutes, negative pressure, or hyperbaric oxygen, many patients still are left with chronic wounds that won’t heal and are costly for the patients and healthcare system. SANUWAVE® is at the forefront of improving upon the standard of care for advanced wounds using our Energy First protocol.
Our solutions help expedite the healing process at the cellular level, resulting in less time and resources spent on costly treatments that are not as effective. SANUWAVE offers a better, simpler alternative to the traditional standard of wound care for improved patient outcomes and enhanced quality of life.
Testimonials
It helps you with regeneration of the tissues. It helps you with new vascularization to create new blood vessels mainly in diabetic microvascular disease. The treatment usually lasts two to four minutes, and it’s not really complicated. It’s pretty easy. This is a good alternative for patients who are not healing. It’s completely brand-new technology; it’s kind of breakthrough compared to what we had so far in wound care.
Results using SANUWAVE’s dermaPACE® System have been very positive in treating diabetic foot ulcers. We put dermaPACE to use on complex DFUs that have not responded to the best practice applied to wounds longer than six months with a marked improvement. I highly recommend that you add this device to all advanced wound centers.
With the dermaPACE® System, all of our diabetic foot ulcer patients that have completed six to 10 weeks of treatment have 100% healed. All patients had ABIs above 0.5 or had no peripheral ischemia with lower limb threatening disease. We are grateful to SANUWAVE for providing this remarkable technology.
I have used the dermaPACE® System in my office since the fall of 2019. It has helped heal severe diabetic wounds that were headed toward amputation. In my opinion, it works as well as HBO without the cost and risks to the patient.
To describe the magic in wound care DFU, it will be the ESWT dermaPACE®.
First case: 63 year-old female, DM with neuropathic foot, on insulin.
Neuropathic ulcer (chronic over 10 months). Osteomyelitis under treatment.
Second case: (chronic over three years) 40 year-old male, DM with neuropathic foot, amputation in 2017 for the big toe, BMI 42, peripheral vascular disease, DM type 1 diagnosed in 2002.
This technology stimulates angiogenesis in the limb. In a patient with diabetes, we normally have decreased blood flow to the foot. This decreased blood flow starves the tissues and causes a skin breakdown and ulcerations. By applying this dermaPACE® technology, we stimulate blood flow to these starved areas, which improves wound healing. When my patients were randomized in the study, we saw a remarkable rate of closure.
I have been using the dermaPACE® System on various types of pressure wounds, typically on hard-to-heal wounds older than six months. The results have been fantastic. I am seeing impressive rates in wound area reduction and healing, results that help me to better manage my patients’ wounds. My goal is to educate my colleagues on this new, noninvasive method of treating pressure wounds.
It is ALWAYS about the patient. We have to stop the high rate of amputations. I treat an average of 70 DFU patients a week and of those, 40% to 45% receive treatment with the dermaPACE® System. I am seeing on average a 12% healing rate per week. I credit this increase in healing rates to using the dermaPACE System and its ability to increase modulate inflammation, perfusion, and new capillary formation.”
The dermaPACE® System has been particularly effective in speeding the healing process through improved microvascular perfusion in patients with diabetic, distal ischemia. We were also able to observe how the dermaPACE System affects the healing of primarily closed wound sites with a dramatic reduction of edema, from between 3-4+ perioperatively to negligible amounts after the third shockwave treatment. The introduction of shockwave therapy to the mix appears to hasten the overall healing affect (wound margin annealing) and allowed the patients to return normal weight-bearing activities sooner.”
Healing chronic wounds remains a challenge for wound care specialists and can lead to loss of function, decreased quality of life, and are a significant cause of morbidity for the patients who suffer with them. Using energy transfer technologies, such as UltraMIST®, has demonstrated improved healing in a variety of recalcitrant and unhealing wounds.”
